Letter: mesalazine—a safe drug with rare serious adverse events? Authors’ reply

LINKED CONTENT This article is linked to Sehgal et al and Scrivo et al papers. To view these articles, visit https://doi.org/10.1111/apt.14688 and https://doi.org/10.1111/apt.15691 .